Last year, GEN presented 25 drugs in the pipeline for diabetes; now we bring you an updated list of drug candidates for which diabetes or complications from diabetes is at least one proposed or approved indication, and for which one indication has reached Phase III registration phases and/or approval or rejection of application. Entries are listed alphabetically.
Transparency Market Research recently reported that the global market for diabetes management accounted for $41.9 billion in 2010 and is expected to attain a market size of $114.3 billion in 2016 following a growth rate of 18.2% CAGR. Accordingly, pharma and biotech firms are developing and clinically testing novel therapeutic formulations and experimenting with a range of delivery systems, some new and others old reliables. These include pens, syringes, smart sponges, oral, and tablets.